Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?

On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study. Following […]